It is known that Inflammation is the underlying cause of COPD and this affects to quality of life of the patient. Provision of inhaled therapy combination of LABA and corticosteroids is one of therapy in pharmacology of stable PPOK patients. The aim of this study was to know the benefits of inhalation of 50 μg/fluticasone propionate 500 μg inhibition in stable COPD patients. The research design is clinical trail. The study was conducted for 3 months and was performed on 26 stable COPD patients divided into two groups: 15 patients for the treatment group and 15 patients for the control group. After the measurements were obtained there was a significant difference in the quality of life as measured by St. George’s respiratory questionnaire (p = 0,001) and COPD assessment test (p = 0,001) measurements were made twice on the first and thirdteenth days.
Acne vulgaris merupakan penyakit peradangan menahun folikel pilosebasea dengan penyebab yang multifaktorial dan gambaran klinis yang beragam. Penelitian ini bertujuan untuk mengetahui hubungan kualitas tidur dengan kejadian acne vulgaris padapasien di praktek dr. Nur Afni, M. Biomed Medan. Penelitian ini merupakan penelitian analitik observasional dengan menggunakan desain crosssectional. Teknik pengambilan sampel yang digunakan adalah total sampling dengan cara menjadikan seluruh populasi menjadi sampel. Dalam penelitian ini 67 responden yang memenuhi kriteria yang ditentukan. Teknik pengumpulan data dengan mewawancara responden menggunakan kuesioner PSQI (pittsburgh sleep quality index) untuk mengukur kualitas tidur responden. Hasil penelitian menunjukan sebanyak 70,7% responden yang mengalami acne vulgaris memiliki kualitas tidur yang buruk. Hasil analisis data diperoleh p-value sebesar 0,025. Kesimpulan dari penelitian ini adalah terdapat hubungan yang signifikan antara kualitas tidur dengan kejadian acne vulgaris sehingga perlu dilakukan edukasi pada mahasiswa agar menjaga kualitas tidur dengan baik untuk mencegah timbulnya acne vulgaris.
It is known that inflammation is the underlying cause of COPD, and this affects to quality of life of the patient. Provision of inhaled therapy combination of LABA and corticosteroids is one of therapy in pharmacology of stable PPOK patients. The aim of this study was to know the benefits of inhalation of 50 g / fluticasone propionate 500 g inhibition in stable COPD patients. The research design is clinical trial. The study was conducted for 3 months and was performed on 26 stable COPD patients divided into two groups: 15 patients for the treatment group and 15 patients for the control group. After the measurements were obtained, there was a significant difference in the quality of life as measured by St. George's Respiratory Questionnaire (SGRQ) (p = 0.001) and COPD Assessment Test (CAT) (0.001) measurements were made twice on the first and thirtieth days.
It is known that inflammation is the underlying cause of COPD, and this affects to quality of life of the patient. Provision of inhaled therapy combination of LABA and corticosteroids is one of therapy in pharmacology of stable PPOK patients. The aim of this study was to know the benefits of inhalation of 50 mg / fluticasone propionate 500 mg inhibition in stable COPD patients. The research design is clinical trial. The study was conducted for 3 months and was performed on 26 stable COPD patients divided into two groups: 15 patients for the treatment group and 15 patients for the control group. After the measurements were obtained, there was a significant difference in the quality of life as measured by St. George's Respiratory Questionnaire (SGRQ) (p = 0.001) and COPD Assessment Test (CAT) (0.001) measurements were made twice on the first and thirtieth days.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.